Humacyte, Inc. (NASDAQ:HUMA) Receives $8.14 Average PT from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has been given an average rating of “Moderate Buy” by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $8.1429.

A number of brokerages recently commented on HUMA. Benchmark decreased their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 21st. UBS Group restated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. BTIG Research reaffirmed a “buy” rating and issued a $6.00 price target on shares of Humacyte in a research note on Monday, February 9th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Humacyte in a research report on Monday, December 1st. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Tuesday.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd acquired a new stake in Humacyte during the 4th quarter worth $25,000. Atom Investors LP bought a new stake in shares of Humacyte in the fourth quarter worth about $25,000. Truist Financial Corp acquired a new stake in shares of Humacyte during the third quarter worth about $28,000. Prudential Financial Inc. acquired a new stake in shares of Humacyte during the second quarter worth about $28,000. Finally, Financial Advisors Network Inc. bought a new position in shares of Humacyte during the 2nd quarter valued at about $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Stock Performance

HUMA stock opened at $1.06 on Friday. Humacyte has a twelve month low of $0.88 and a twelve month high of $3.36. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. The company has a market cap of $198.51 million, a P/E ratio of -4.61 and a beta of 1.89. The business’s fifty day moving average is $1.09 and its 200-day moving average is $1.31.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.